Michael F Grunebaum1, Steven P Ellis1, John G Keilp1, Vivek K Moitra2, Thomas B Cooper3, Julia E Marver1, Ainsley K Burke1, Matthew S Milak1, M Elizabeth Sublette1, Maria A Oquendo4, J John Mann1. 1. Molecular Imaging and Neuropathology Division, Department of Psychiatry, Columbia University Medical Center (CUMC) and New York State Psychiatric Institute, New York, NY, USA. 2. Department of Anesthesiology, CUMC, New York, NY, USA. 3. Analytical Psychopharmacology Laboratory, Nathan Kline Institute, Research Foundation for Mental Hygiene of New York State, Orangeburg, NY, USA. 4. Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Abstract
OBJECTIVES: To evaluate feasibility and effects of a sub-anesthetic infusion dose of ketamine versus midazolam on suicidal ideation in bipolar depression. Neurocognitive, blood and saliva biomarkers were explored. METHODS:Sixteen participants with bipolar depression and a Scale forSuicidal Ideation (SSI) score of ≥4 were randomized to ketamine (0.5 mg/kg) or midazolam (0.02 mg/kg). Current pharmacotherapy was maintained excluding benzodiazepines within 24 hours. The primary clinical outcome was SSI score on day 1 post-infusion. RESULTS: Results supported feasibility. Mean reduction of SSI after ketamine infusion was almost 6 points greater than after midazolam, although this was not statistically significant (estimate=5.84, SE=3.01, t=1.94, P=.074, 95% confidence interval ([CI)]=-0.65 to 12.31). The number needed to treat for response (SSI <4 and at least 50% below baseline) was 2.2, and for remission (SSI=0) was 3.2. The strongest neurocognitive correlation was between memory improvement on the Selective Reminding Test (SRT) and reduction in SSI score on day 1 after ketamine (ρ=-.89, P=.007). Pre- to post-infusion decrease in serum brain derived neurotrophic factor (BDNF) correlated with reduction in SSI from baseline to day 1 after ketamine (n=5, ρ=0.90, P=.037) but not midazolam (P=.087). CONCLUSIONS: The study demonstrated feasibility. Suicidal thoughts were lower after ketamine than after midazolam at a trend level of significance, likely due to the small pilot sample. Memory improvement and BDNF are promising biomarkers. Replication is needed in an adequately powered full-scale trial.
RCT Entities:
OBJECTIVES: To evaluate feasibility and effects of a sub-anesthetic infusion dose of ketamine versus midazolam on suicidal ideation in bipolar depression. Neurocognitive, blood and saliva biomarkers were explored. METHODS: Sixteen participants with bipolar depression and a Scale for Suicidal Ideation (SSI) score of ≥4 were randomized to ketamine (0.5 mg/kg) or midazolam (0.02 mg/kg). Current pharmacotherapy was maintained excluding benzodiazepines within 24 hours. The primary clinical outcome was SSI score on day 1 post-infusion. RESULTS: Results supported feasibility. Mean reduction of SSI after ketamine infusion was almost 6 points greater than after midazolam, although this was not statistically significant (estimate=5.84, SE=3.01, t=1.94, P=.074, 95% confidence interval ([CI)]=-0.65 to 12.31). The number needed to treat for response (SSI <4 and at least 50% below baseline) was 2.2, and for remission (SSI=0) was 3.2. The strongest neurocognitive correlation was between memory improvement on the Selective Reminding Test (SRT) and reduction in SSI score on day 1 after ketamine (ρ=-.89, P=.007). Pre- to post-infusion decrease in serum brain derived neurotrophic factor (BDNF) correlated with reduction in SSI from baseline to day 1 after ketamine (n=5, ρ=0.90, P=.037) but not midazolam (P=.087). CONCLUSIONS: The study demonstrated feasibility. Suicidal thoughts were lower after ketamine than after midazolam at a trend level of significance, likely due to the small pilot sample. Memory improvement and BDNF are promising biomarkers. Replication is needed in an adequately powered full-scale trial.
Authors: Nolan R Williams; Boris D Heifets; Brandon S Bentzley; Christine Blasey; Keith D Sudheimer; Jessica Hawkins; David M Lyons; Alan F Schatzberg Journal: Mol Psychiatry Date: 2019-08-29 Impact factor: 15.992
Authors: Elizabeth D Ballard; Julia S Yarrington; Cristan A Farmer; Erica Richards; Rodrigo Machado-Vieira; Bashkim Kadriu; Mark J Niciu; Peixiong Yuan; Lawrence Park; Carlos A Zarate Journal: J Affect Disord Date: 2018-07-30 Impact factor: 4.839
Authors: Samuel T Wilkinson; Cristan Farmer; Elizabeth D Ballard; Sanjay J Mathew; Michael F Grunebaum; James W Murrough; Peter Sos; Gang Wang; Ralitza Gueorguieva; Carlos A Zarate Journal: Neuropsychopharmacology Date: 2019-01-17 Impact factor: 7.853
Authors: Michael F Grunebaum; Hanga C Galfalvy; Tse-Hwei Choo; Michelle S Parris; Ainsley K Burke; Raymond F Suckow; Thomas B Cooper; J John Mann Journal: J Psychiatr Res Date: 2019-08-09 Impact factor: 4.791
Authors: Gustavo C Medeiros; Todd D Gould; William L Prueitt; Julie Nanavati; Michael F Grunebaum; Nuri B Farber; Balwinder Singh; Sudhakar Selvaraj; Rodrigo Machado-Vieira; Eric D Achtyes; Sagar V Parikh; Mark A Frye; Carlos A Zarate; Fernando S Goes Journal: Mol Psychiatry Date: 2022-06-27 Impact factor: 15.992